Want to see JP:2784 full AI Analyst Report?
Top Page
Alfresa Holdings
(2784)
Select Model
Select Model
Rating:63Neutral
Price Target:
¥2,396.00
▲(3.03% Upside)
Action:Reiterated
Date:08/17/26
The score is primarily supported by a strong, low-debt balance sheet and steady revenue growth, while being held back by inconsistent cash-flow conversion and thin operating margins. Valuation is a positive offset (low P/E and ~3% yield), but technical indicators remain weak-to-neutral with the price below key long-term moving averages.
Positive Factors
Conservative balance sheet
Low leverage and a stronger equity base provide durable financial flexibility for a distribution business that needs to hold inventory and fund working capital. This footing reduces default risk and supports strategic investments or M&A without pressuring cash flow in downturns.
Negative Factors
Very thin operating and net margins
Extremely narrow margins leave earnings highly sensitive to cost increases, reimbursement shifts or pricing competition. With limited margin buffer, small adverse changes can meaningfully reduce profitability and constrain reinvestment or dividend capacity over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Low leverage and a stronger equity base provide durable financial flexibility for a distribution business that needs to hold inventory and fund working capital. This footing reduces default risk and supports strategic investments or M&A without pressuring cash flow in downturns.
Read all positive factors
Alfresa Holdings (2784) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥440.53B
Dividend Yield2.95%
Average Volume (3M)496.94K
Price to Earnings (P/E)10.7
Beta (1Y)0.47
Revenue Growth4.61%
EPS Growth43.22%
CountryJP
Employees12,525
SectorGeneral
Sector StrengthN/A
IndustryMedical - Distribution
Share Statistics
EPS (TTM)216.01
Shares Outstanding191,300,000
10 Day Avg. Volume381,110
30 Day Avg. Volume496,943
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)0.91
Price to Sales (P/S)0.15
P/FCF Ratio28.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥2,500.00Price Target Upside7.50% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)135.63
Revenue Forecast (FY)¥3.17T
Alfresa Holdings Business Overview & Revenue Model
Company Description
Alfresa Holdings Corporation, a Japanese company established in Tokyo in 2003, operates globally through its subsidiaries, specializing in the production, wholesale distribution, marketing, and international trade of pharmaceuticals, diagnostic re...
How the Company Makes Money
Alfresa Holdings makes money primarily by acting as an intermediary in the pharmaceutical supply chain, purchasing pharmaceuticals and other healthcare products from manufacturers and selling them to customers such as hospitals, clinics, and pharm...
Alfresa Holdings Financial Statement Overview
Summary
Income Statement
64
Positive
Balance Sheet
82
Very Positive
Cash Flow
46
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.13T | 3.10T | 2.96T | 2.86T | 2.70T | 2.59T |
| Gross Profit | 218.81B | 217.88B | 202.71B | 196.36B | 182.26B | 178.31B |
| EBITDA | 75.92B | 77.41B | 54.56B | 57.44B | 51.96B | 61.08B |
| Net Income | 39.22B | 41.75B | 27.39B | 29.56B | 25.79B | 32.18B |
Balance Sheet | ||||||
| Total Assets | 1.51T | 1.51T | 1.44T | 1.45T | 1.34T | 1.30T |
| Cash, Cash Equivalents and Short-Term Investments | 192.07B | 193.07B | 177.09B | 213.76B | 160.12B | 180.44B |
| Total Debt | 30.00B | 35.62B | 35.55B | 34.94B | 3.85B | 5.04B |
| Total Liabilities | 1.02T | 999.11B | 957.63B | 967.76B | 851.51B | 832.15B |
| Stockholders Equity | 485.64B | 507.36B | 481.79B | 479.60B | 488.09B | 471.59B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 16.11B | -10.87B | 73.64B | -9.63B | 21.54B |
| Operating Cash Flow | 0.00 | 38.57B | 5.64B | 86.38B | 13.09B | 36.55B |
| Investing Cash Flow | 0.00 | -8.72B | -24.92B | -14.22B | -20.54B | 2.30B |
| Financing Cash Flow | 0.00 | -14.05B | -23.53B | -19.70B | -12.92B | -29.15B |
Alfresa Holdings Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | ¥529.54B | 12.85 | 7.26% | 2.26% | 4.17% | 15.59% | |
71 Outperform | ¥293.02B | 9.51 | 9.19% | 1.94% | 4.65% | 23.21% | |
69 Neutral | ¥435.66B | 13.85 | 11.15% | 3.52% | 4.32% | 0.18% | |
69 Neutral | ¥516.88B | 15.70 | 10.75% | 1.88% | 12.20% | -25.42% | |
63 Neutral | ¥440.53B | 10.69 | 7.93% | 2.95% | 4.61% | 43.22% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
52 Neutral | ¥403.30B | 23.80 | ― | 0.35% | 13.04% | -0.05% |
* General Sector Average
JP:2784
Alfresa Holdings
2,308.50
93.59
4.23%
JP:7459
Medipal Holdings
2,919.00
273.47
10.34%
JP:9989
Sundrug Co
3,726.00
-791.78
-17.53%
JP:7649
Sugi Holdings Co
1,330.00
-579.44
-30.35%
JP:9987
Suzuken Co
5,162.00
-809.69
-13.56%
JP:3549
KUSURI NO AOKI HOLDINGS CO.,LTD.
4,218.00
279.84
7.11%
Alfresa Holdings Corporate Events
Alfresa’s Q1 Profits Slide Despite Higher Sales, Full-Year Outlook Intact
Aug 5, 2026
Alfresa Holdings reported consolidated net sales of ¥788.96 billion for the quarter ended June 30, 2026, up 4.1% year on year, but profits fell sharply as operating profit dropped 19.6% to ¥5.6 billion and profit attributable to owners o...
Alfresa Sets Terms for Japanese ASR-Linked Stock Acquisition Rights
May 18, 2026
Alfresa Holdings has set the terms for its first issuance of stock acquisition rights via a third-party allotment, tied to a fully committed share repurchase program conducted through the Tokyo Stock Exchange’s ToSTNeT-3 system. The structur...
Alfresa Completes ¥15 Billion Share Buyback to Boost Capital Efficiency
May 18, 2026
Alfresa Holdings has completed a ¥14.99 billion share repurchase, buying 6,307,800 common shares, equivalent to 3.5% of its outstanding stock excluding treasury shares, through the Tokyo Stock Exchange’s off-auction ToSTNeT-3 system on ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.